Study finds six different COVID-19 vaccine boosters increase immunity and pose no safety concerns, although immune responses varied.
List view / Grid view
Production of CureVac’s CVnCoV vaccine will take place in Germany, with over 50 million doses expected to be produced in 2021.
The rolling review will assess CVnCoV’s efficacy and immunogenicity data as it becomes available, speeding the decision process for an eventual marketing authorisation application.
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
The first participant has been enrolled in a Phase IIb/III study of CVnCoV, CureVac's mRNA COVID-19 vaccine candidate.
The interim Phase I data suggests CVnCoV can safely induce a neutralising antibody response similar to that of convalescent COVID-19 patients with two 12μg vaccine doses.
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.